Tarsus Pharmaceuticals, Inc. (TARS) Financial Statements (2026 and earlier)

Company Profile

Business Address 15440 LAGUNA CANYON ROAD
IRVINE, CA 92618
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments417,267291,375227,442217,026171,815168,129
Cash and cash equivalent183,64094,818224,94771,660171,332168,129
Short-term investments233,627196,5572,495145,366483 
Restricted cash and investments 560    20
Receivables87,10948,05917,7143,5829220
Inventory, net of allowances, customer advances and progress billings4,3722,6203,107   
Inventory4,3722,6203,107   
Prepaid expense13,47314,6507,8684,767 2,486
Other undisclosed current assets 11  4,045 
Total current assets:522,782356,705256,131225,375175,952170,655
Noncurrent Assets
Inventory, Noncurrent2,5322,533    
Operating lease, right-of-use asset10,0805521,8805751,074688
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization11,6652,3141,468957755548
Long-term investments and receivables3,8703,000631371  
Long-term investments3,8703,000631371  
Intangible asset, including goodwill, after accumulated amortization7,3668,3263,867   
Intangible asset, excluding goodwill, after accumulated amortization7,3668,3263,867   
Restricted cash and investments2,0022,562    
Other noncurrent assets1,8619991,5145851,12681
Total noncurrent assets:39,37620,2869,3602,4882,9551,317
TOTAL ASSETS:562,158376,991265,491227,863178,907171,972
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities104,41676,68418,1125,7482,8531,040
Taxes payable✕✕✕✕✕55 
Employee-related liabilities✕✕✕✕✕2,7981,040
Accounts payable16,38727,739    
Accrued liabilities88,02948,94518,1125,748  
Deferred revenue     697 
Deferred compensation liability     56304
Other liabilities22,179     
Other undisclosed current liabilities9,1003,92818,8249,6817,8724,043
Total current liabilities:135,69580,61236,93615,42911,4785,387
Noncurrent Liabilities
Long-term debt and lease obligation72,43871,84529,81919,434  
Long-term debt, excluding current maturities72,43871,84529,81919,434  
Liabilities, other than long-term debt10,599 1,748100699605
Other liabilities10,599 1,748100699605
Total noncurrent liabilities:83,03771,84531,56719,534699605
Total liabilities:218,732152,45768,50334,96312,1775,992
Equity
Equity, attributable to parent343,426224,534196,988192,900166,730165,980
Common stock665544
Additional paid in capital769,667584,559441,641301,732213,398198,821
Accumulated other comprehensive income (loss)381179(2)(74)  
Accumulated deficit(426,628)(360,210)(244,656)(108,763)(46,672)(32,845)
Total equity:343,426224,534196,988192,900166,730165,980
TOTAL LIABILITIES AND EQUITY:562,158376,991265,491227,863178,907171,972

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues451,360182,95317,44725,81657,027 
Cost of revenue(29,723)(12,286)    
Cost of product and service sold      
Gross profit:421,637170,66717,44725,81657,027 
Operating expenses(492,606)(291,236)(160,605)(88,528)(69,184)(26,998)
Operating loss:(70,969)(120,569)(143,158)(62,712)(12,157)(26,998)
Nonoperating income (expense)6,6105,0157,265617(1,615)188
Interest and debt expense(8,935)(1,944)(3,346)(2,199)  
Loss from continuing operations before equity method investments, income taxes:(73,294)(117,498)(139,239)(64,294)(13,772)(26,810)
Other undisclosed income from continuing operations before income taxes8,9351,9443,3462,199  
Loss from continuing operations before income taxes:(64,359)(115,554)(135,893)(62,095)(13,772)(26,810)
Income tax expense (benefit)(2,059)  4(55)(1)
Other undisclosed loss from continuing operations      
Loss from continuing operations:(66,418)(115,554)(135,893)(62,091)(13,827)(26,811)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(13,827)(26,811)
Net loss:(66,418)(115,554)(135,893)(62,091)(13,827)(26,811)
Other undisclosed net loss attributable to parent      
Net loss available to common stockholders, diluted:(66,418)(115,554)(135,893)(62,091)(13,827)(26,811)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(66,418)(115,554)(135,893)(62,091)(13,827)(26,811)
Other comprehensive income (loss)20218172(74)  
Other undisclosed comprehensive income      
Comprehensive loss:(66,216)(115,373)(135,821)(62,165)(13,827)(26,811)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(66,216)(115,373)(135,821)(62,165)(13,827)(26,811)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: